Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.47 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.47 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.47 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 2/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.43 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638037 | 0.77 | L3MBTL1 (0.51) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3637367 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3638458 | 0.76 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3638402 | 0.75 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3639418 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3638704 | 0.74 | HDAC1 (0.56) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3632674 | 0.74 | SMN1; SMN2 (0.50) | SMN1; SMN2L3MBTL1HPGDFRKCAMK2B | |
| SCHEMBL3112901 | 0.74 | ALDH1A1 (0.41) | SMN1; SMN2L3MBTL1HPGDMAPTALDH1A1 | |
| SCHEMBL30814237 | 0.74 | ALDH1A1 (0.41) | SMN1; SMN2L3MBTL1HPGDMAPTALDH1A1 | |
| SCHEMBL3636234 | 0.73 | PPARA (0.61) | SMN1; SMN2L3MBTL1HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242933-B2 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor) | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-01-26 | — | — | US | disclosed |
| EP-2167464-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | Abbott GmbH & Co. KG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008145616-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 RECEPTOR) | ABBOTT GMBH & CO. KG (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300260-A1 | HETEROCYCLIC COMPOUNDS AS POSITIVE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR 2 (MGLU2 receptor) | GRM2, GRIN2C, GRM1 | SMN1; SMN2 1228/4885L3MBTL1 4483/4885HPGD 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.